Arnatar

Arnatar was founded in 2022 and is committed to becoming a high-tech innovative drug research and development enterprise with independent intellectual property rights, using novel antisense nucleic acid technologies (siRNA and ASO) as its platform. Arnatar's founding team consists of world-renowned experts in the field of antisense nucleic acid pharmaceuticals and drug development, working alongside industry veterans with years of experience in RNA Biology, drug target selection, and small nucleic acid chemical synthesis. Currently, Arnatar is focusing on the research and development of innovative drugs based on novel antisense nucleic acid technologies, primarily developing nucleic acid drugs for treating common metabolic diseases and severe rare diseases with liver-targeted and extrahepatic-targeted therapies.